A Phase II Randomized Trial of Camrelizumab With Stereotactic Body Radiotherapy Versus Camrelizumab Alone in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Latest Information Update: 01 Apr 2024
At a glance
- Drugs Camrelizumab (Primary)
- Indications Head and neck cancer; Nasopharyngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 26 Mar 2024 Planned number of patients changed from 70 to 39.
- 07 Apr 2021 New trial record